ShouTi Appoints Sharon Tetlow to Board of Directors

Rhea-AI Summary

ShouTi Inc., a clinical-stage biopharmaceutical company, has appointed Sharon Tetlow to its board of directors, where she will also chair the audit committee. With over 30 years of experience in life sciences finance, Tetlow has previously held senior roles including CFO at various biopharmaceutical firms. She currently serves on the boards of Dice Therapeutics (DICE), Valneva SE (VALN), and Catalyst Biosciences (CBIO). Her expertise is expected to strengthen ShouTi's growth strategy as the company focuses on developing innovative oral therapeutics for chronic diseases.

Positive

• Sharon Tetlow's extensive experience in life sciences finance may enhance strategic decision-making.
• Tetlow's role as chair of the audit committee is expected to improve financial oversight.

Negative

• Concerns about management continuity given a recent board appointment.

SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)-- ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company’s board of directors. Ms. Tetlow will also serve as chair of the audit committee.

“On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board,” said Daniel Welch, Chairman of the Board, ShouTi. “Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee. With an outstanding track record of advising biopharmaceutical companies, Sharon’s perspective will help propel us into our next stage of growth in bringing more effective and globally-accessible treatments to patients with chronic diseases.”

Ms. Tetlow has more than 30 years of financial leadership experience within the life sciences industry. She founded and serves as Managing Partner of Potrero Hill Advisors (PHA). Prior to PHA, Ms. Tetlow held numerous senior finance roles, including Chief Financial Officer, at multiple public and private life sciences companies. Ms. Tetlow is an experienced board director and currently serves as board member, Audit Committee Chair and member of the Nominating and Governance Committee of Dice Therapeutics (NASDAQ: DICE), as Supervisory Board Member and Audit Committee Chair of Valneva SE (NASDAQ: VALN) and as board member and Audit Committee Chair of Catalyst Biosciences (NASDAQ: CBIO). Ms. Tetlow earned a B.A. from the University of Delaware, and an M.B.A. from Stanford University.

“With its powerful structure-based drug discovery engine and pipeline of novel small molecule drug candidates, I believe ShouTi has a unique opportunity to bring impactful medicines to the world,” said Ms. Tetlow. “I’m excited to join the ShouTi board to help shape the company’s evolution and drive our mission of developing innovative oral therapeutics to treat a wide range of diseases within the metabolic, cardiovascular and pulmonary therapeutic areas.”

About ShouTi

ShouTi is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. ShouTi’s pipeline includes two clinical compounds. The company’s cutting-edge technology platform leverages structure-based drug discovery and computational chemistry expertise and enables ShouTi to develop oral small molecule therapeutics for the treatment of various diseases, including those in the metabolic, cardiovascular, and pulmonary therapeutic areas. By leveraging ShouTi’s world-class structure-based drug discovery know-how, the company aims to design differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies, starting with a focus on the GPCR family of drug targets. For more information, visit www.shoutipharma.com and follow the company on Twitter @ShouTiPharma and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005140/en/

Media

Ian Stone

Canale Communications

media@shoutipharma.com

For other inquiries:

Melita Sun Jung

Chief Business Officer

info@shoutipharma.com

Source: ShouTi Inc.

FAQ

What is the significance of Sharon Tetlow's appointment to ShouTi Inc. on March 29, 2023?

Sharon Tetlow's appointment enhances ShouTi's financial leadership and strategic direction, as she brings over 30 years of experience in life sciences finance.

How might Sharon Tetlow's experience impact ShouTi Inc.'s future growth?

Tetlow's background in advising biopharmaceutical companies could lead to improved financial strategies and compliance, crucial for ShouTi's development efforts.

Who are the other companies where Sharon Tetlow holds board positions?

Sharon Tetlow is on the boards of Dice Therapeutics (DICE), Valneva SE (VALN), and Catalyst Biosciences (CBIO), enhancing her influence in the biopharmaceutical sector.

What are ShouTi's primary therapeutic focuses as of 2023?

ShouTi aims to develop novel oral therapeutics for chronic diseases, particularly within metabolic, cardiovascular, and pulmonary therapeutic areas.